Mw. Haymond et al., EFFECT OF HUMAN GROWTH-HORMONE AND INSULIN-LIKE GROWTH FACTOR-I ON WHOLE-BODY LEUCINE AND ESTIMATES OF PROTEIN-METABOLISM, Hormone research, 40(1-3), 1993, pp. 92-94
Recombinant human growth hormone (rhGH) administration to normal volun
teers increases estimates of whole-body and forearm protein synthesis
but has little effect on rates of proteolysis in both the postabsorpti
ve state and during meal absorption. In contrast, insulin decreases es
timates of whole-body and forearm proteolysis while decreasing or, in
the presence of infused (or ingested) amino acids, sustaining estimate
s of protein synthesis. We have used high-dose prednisone as a control
led model for protein catabolism in normal volunteers and demonstrated
that glucocorticosteroids increase estimates of whole-body proteolysi
s and the oxidation of leucine with little or no effect on estimates o
f whole-body protein synthesis. We have recently demonstrated that hig
h-dose rhGH together with prednisone prevents the protein-catabolic ef
fects observed with treatment with prednisone alone, while inducing in
sulin resistance and increased secretion of proinsulin. GH is thought
to mediate its effects via the generation of insulin-like growth facto
r I (IGF-I). However, high rates of infusion of rhIGF-I induce hypogly
cemia and decrease estimates of whole-body proteolysis and suppress th
e secretion of GH, insulin and glucagon, suggesting a predominant insu
lin-like effect on protein and glucose metabolism. When rhIGF-I is inf
used at a rate that achieves plasma IGF-I concentrations similar to th
ose observed during rhGH treatment and yet avoids hypoglycemia, estima
tes of proteolysis and protein synthesis were not affected in the abse
nce or presence of prednisone treatment.When rhGH and rhIGF-I are admi
nistered simultaneously, nitrogen balance is remarkably improved. Thus
, the mechanism of action of both rhGH and/or rhIGF-I on body protein
metabolism remains to be elucidated. However, rhGH alone or in combina
tion with rhIGF-I may provide a new management strategy in a variety o
f protein-catabolic conditions in humans.